Association between circulating vitamin E and ten common cancers: evidence from large-scale Mendelian randomization analysis and a longitudinal cohort study

Table 1 Statistical power in Mendelian randomization (MR) study of circulating vitamin E and cancer risk in cancer-specific GWAS

Cancer type	Sample size (N = 602,435)		F-statistics	Minimum detectable OR^a
Cancer type	Cases (N = 297,699)	Controls (N = 304,736)	F-statistics	Minimum detectable OR^a
Bladder cancer	5930	5468	198.12	0.67/1.49
Breast cancer	122,977	105,974	3960.48	0.91/1.09
Colorectal cancer	24,476	23,073	823.31	0.82/1.22
Esophagus cancer	2268	1865	72.48	0.53/1.97
Lung cancer	29,266	56,450	1483.37	0.85/1.16
Oral and pharynx cancer	4950	2907	136.88	0.63/1.70
Ovarian cancer	22,406	40,941	1096.52	0.83/1.19
Pancreatic cancer	4970	3532	148.03	0.64/1.63
Prostate cancer	79,148	61,106	2426.55	0.89/1.12
Kidney cancer	1308	3420	82.77	0.44/1.81

^aMinimum detectable OR (per 1 SD of vitamin E) was calculated based on 80% power, 5% alpha level, and 1.7% of vitamin E variance (R²) explained by 3 SNPs used in this study

ISSN: 1741-7015